Novogen Ltd Ads (NVGN) 1.83 $NVGN
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant
PR Newswire - Tue Jun 14, 6:00AM CDT
US-Australian drug discovery company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted in Australia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507).
NVGN: 1.83 (-0.03)
Novogen Provides Update On Development Of Cantrixil
PR Newswire - Mon May 02, 6:00AM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer.
Q: 78.61 (+0.97), NVGN: 1.83 (-0.03)
Novogen Receives R&D Tax Incentive Cash Refund
PR Newswire - Wed Mar 16, 9:02PM CDT
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2015. This will support the Company's preparations to progress Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) drug candidate, to Phase 1 clinical trial in 2016.
NVGN: 1.83 (-0.03)
TapImmune Tackles Ovarian Cancer in Fast Track Phase II Clinical Trials
ACCESSWIRE - Tue Feb 09, 8:00AM CST
Fast Track Label and Orphan Drug Designation granted for Ovarian cancer indication following positive data; Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion cancer drug market
CERU: 2.89 (unch), MRK: 58.66 (unch), NVGN: 1.83 (-0.03), ATRA: 24.40 (+0.40), BMY: 76.19 (+1.38)
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
PR Newswire - Fri Feb 05, 1:20AM CST
Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of a new Chairman, Mr John O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately.
NVGN: 1.83 (-0.03)
Novogen appoints Dr James Garner as CEO
M2 - Thu Dec 10, 3:57AM CST
Drug company Novogen (ASX:NRT)( NASDAQ:NVGN) reported on Wednesday that it has appointed Dr James Garner as its chief executive officer and as a member of its board of directors.
NVGN: 1.83 (-0.03), NRT: 8.79 (-0.85)
Novogen Appoints Dr James Garner as Chief Executive Officer
PR Newswire - Wed Dec 09, 3:59PM CST
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of Directors of Novogen.
NVGN: 1.83 (-0.03)
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial
PR Newswire - Tue Nov 24, 6:00AM CST
-- Novogen engages Novotech as CRO for upcoming Phase 1 clinical study
NVGN: 1.83 (-0.03)
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia
PR Newswire - Thu Nov 12, 6:00AM CST
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia.
NVGN: 1.83 (-0.03)
Novogen's patent for Cantrixil and Trilexium under SBP discovery programme accepted in Australia
M2 - Thu Nov 12, 3:31AM CST
Drug company Novogen Limited (ASX:NRT)(NASDAQ:NVGN) disclosed on Wednesday the acceptance of its patent application covering two of its key lead superbenzopyran (SBP) drug candidates in Australia.
NVGN: 1.83 (-0.03), NRT: 8.79 (-0.85)
Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina
PR Newswire - Tue Nov 10, 4:34PM CST
US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of preclinical studies which confirm the efficacy of the lead anti-tropomyosin (ATM) compound, Anisina, when delivered using a clinically relevant formulation, mode of administration and dosing regimen.
NVGN: 1.83 (-0.03)
Novogen (NVGN) Conducts Scientific Review of R&D Program
Zacks Equity Research - Zacks Investment Research - Mon Aug 31, 1:20PM CDT
Novogen Limited (NVGN) announced results from a comprehensive scientific review of its research and development programs.
VRX: 20.89 (-1.41), ADHD: 4.31 (+0.03), UTHR: 125.08 (+4.07), NVGN: 1.83 (-0.03)
BUYINS.NET: NVGN, PSCE Removed From Naked Short Lists Today
M2 - Fri Aug 07, 10:40AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been After the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Powershares S & P Small Cap Energy Portfolio (NASDAQ
SCE). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NVGN: 1.83 (-0.03), PSCE: 14.97 (-0.68)
Newly Appointed Acting CEO Outlines Immediate Plans for Novogen
PR Newswire - Wed Jul 29, 6:54PM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed it is committed to progressing its ground-breaking technology platforms to Phase 1 clinical trials as soon as practicable and to ensure the Company delivers the best value for shareholders.
NVGN: 1.83 (-0.03)
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board
PR Newswire - Wed Jul 22, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made.
NVGN: 1.83 (-0.03)
Anisina awarded orphan drug designation from US FDA for Anisina for treating Neuroblastoma
M2 - Fri Jul 17, 3:21AM CDT
Drug company Novogen (Nasdaq:NVGN) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation for its chemotherapy candidate drug, Anisina, for neuroblastoma, a cancer that is most frequently observed in the young and the most common solid tumour in children outside the brain.
NVGN: 1.83 (-0.03)
Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma
PR Newswire - Thu Jul 16, 6:30AM CDT
US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.
NVGN: 1.83 (-0.03)
Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer
PR Newswire - Mon Jul 13, 3:30PM CDT
US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.
NVGN: 1.83 (-0.03)
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant
PR Newswire - Tue Jun 14, 6:00AM CDT
US-Australian drug discovery company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that a patent for the ATM-3500 series had been granted in Australia. The ATM-3500 series includes the investigational agent known as Anisina (ATM-3507).
NVGN: 1.83 (-0.03)
Novogen Provides Update On Development Of Cantrixil
PR Newswire - Mon May 02, 6:00AM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer.
Q: 78.61 (+0.97), NVGN: 1.83 (-0.03)
Novogen Receives R&D Tax Incentive Cash Refund
PR Newswire - Wed Mar 16, 9:02PM CDT
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced that it has received a cash refund of $2.8M from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2015. This will support the Company's preparations to progress Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) drug candidate, to Phase 1 clinical trial in 2016.
NVGN: 1.83 (-0.03)
TapImmune Tackles Ovarian Cancer in Fast Track Phase II Clinical Trials
ACCESSWIRE - Tue Feb 09, 8:00AM CST
Fast Track Label and Orphan Drug Designation granted for Ovarian cancer indication following positive data; Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion cancer drug market
CERU: 2.89 (unch), MRK: 58.66 (unch), NVGN: 1.83 (-0.03), ATRA: 24.40 (+0.40), BMY: 76.19 (+1.38)
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
PR Newswire - Fri Feb 05, 1:20AM CST
Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today the appointment of a new Chairman, Mr John O'Connor, and new Deputy Chairman, Mr Bryce Carmine, effective immediately.
NVGN: 1.83 (-0.03)
Novogen appoints Dr James Garner as CEO
M2 - Thu Dec 10, 3:57AM CST
Drug company Novogen (ASX:NRT)( NASDAQ:NVGN) reported on Wednesday that it has appointed Dr James Garner as its chief executive officer and as a member of its board of directors.
NVGN: 1.83 (-0.03), NRT: 8.79 (-0.85)
Novogen Appoints Dr James Garner as Chief Executive Officer
PR Newswire - Wed Dec 09, 3:59PM CST
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of Directors of Novogen.
NVGN: 1.83 (-0.03)
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial
PR Newswire - Tue Nov 24, 6:00AM CST
-- Novogen engages Novotech as CRO for upcoming Phase 1 clinical study
NVGN: 1.83 (-0.03)
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia
PR Newswire - Thu Nov 12, 6:00AM CST
US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that a patent application covering two of its key lead superbenzopyran (SBP) drug candidates has been accepted in Australia.
NVGN: 1.83 (-0.03)
Novogen's patent for Cantrixil and Trilexium under SBP discovery programme accepted in Australia
M2 - Thu Nov 12, 3:31AM CST
Drug company Novogen Limited (ASX:NRT)(NASDAQ:NVGN) disclosed on Wednesday the acceptance of its patent application covering two of its key lead superbenzopyran (SBP) drug candidates in Australia.
NVGN: 1.83 (-0.03), NRT: 8.79 (-0.85)
Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina
PR Newswire - Tue Nov 10, 4:34PM CST
US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of preclinical studies which confirm the efficacy of the lead anti-tropomyosin (ATM) compound, Anisina, when delivered using a clinically relevant formulation, mode of administration and dosing regimen.
NVGN: 1.83 (-0.03)
Novogen (NVGN) Conducts Scientific Review of R&D Program
Zacks Equity Research - Zacks Investment Research - Mon Aug 31, 1:20PM CDT
Novogen Limited (NVGN) announced results from a comprehensive scientific review of its research and development programs.
VRX: 20.89 (-1.41), ADHD: 4.31 (+0.03), UTHR: 125.08 (+4.07), NVGN: 1.83 (-0.03)
BUYINS.NET: NVGN, PSCE Removed From Naked Short Lists Today
M2 - Fri Aug 07, 10:40AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been After the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Powershares S & P Small Cap Energy Portfolio (NASDAQ
SCE). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net . NVGN: 1.83 (-0.03), PSCE: 14.97 (-0.68)
Newly Appointed Acting CEO Outlines Immediate Plans for Novogen
PR Newswire - Wed Jul 29, 6:54PM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed it is committed to progressing its ground-breaking technology platforms to Phase 1 clinical trials as soon as practicable and to ensure the Company delivers the best value for shareholders.
NVGN: 1.83 (-0.03)
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board
PR Newswire - Wed Jul 22, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made.
NVGN: 1.83 (-0.03)
Anisina awarded orphan drug designation from US FDA for Anisina for treating Neuroblastoma
M2 - Fri Jul 17, 3:21AM CDT
Drug company Novogen (Nasdaq:NVGN) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation for its chemotherapy candidate drug, Anisina, for neuroblastoma, a cancer that is most frequently observed in the young and the most common solid tumour in children outside the brain.
NVGN: 1.83 (-0.03)
Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma
PR Newswire - Thu Jul 16, 6:30AM CDT
US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.
NVGN: 1.83 (-0.03)
Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer
PR Newswire - Mon Jul 13, 3:30PM CDT
US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.
NVGN: 1.83 (-0.03)
